Activation of a slow outward current by the calcium released during contraction of cultured rat skeletal muscle cells.
A slow outward current, activated during depolarization, which induced contraction in whole-cell patch-clamped rat skeletal muscle cells in primary culture [10], was extensively characterized in the present study. This current, Io, was simultaneously recorded with the contraction as a slow outward current during the test pulse, and a slow outward bell-shaped tail after repolarization. Io never appeared below the threshold potential for contraction, and the tail amplitude displayed a similar evolution with peak contraction amplitude as a function of membrane potential. This feature is consistent with the fact that Io was suppressed when contraction was blocked by 5 microM nifedipine [10], and it suggests that Io was dependent on calcium released during contraction. This was confirmed by the fact that the presence of 10 mM EGTA in the patch pipette prevented the development of both contraction and Io, and that Io could be activated during caffeine-induced contractures without applying depolarizations. Io could be carried by K+ or Cs+ ions, but not by Na+. The pharmacology of Io was different from that of Ca(2+)-dependent BK and SK channels, since it was resistant to tetraethylammonium (135 mM), charybdotoxin (25 nM) and apamin (50 nM). Io was also insensitive to 4-aminopyridine (1 mM) but blocked by 5 mM Ba2+ without change to contraction. It was concluded that rat cultured myoballs exhibit a Cs+ permeation through an atypical K+ channel type, which is activated by the calcium released during contraction.
Constantin
B
B
Laboratoire de Physiologie Générale, URA CNRS no. 290, Université de Poitiers, France.
Cognard
C
C
Rivet-Bastide
M
M
Raymond
G
G
D015761:4-Aminopyridine / Q000494:pharmacology; D000818:Animals; D001030:Apamin / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002478:Cells, Cultured; D002586:Cesium / Q000494:pharmacology; D018999:Charybdotoxin; D004533:Egtazic Acid / Q000494:pharmacology; D004553:Electric Conductivity; D004558:Electric Stimulation; D008564:Membrane Potentials / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009132:Muscles / Q000187:drug effects / Q000502:physiology*; D009543:Nifedipine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D012604:Scorpion Venoms / Q000494:pharmacology; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000494:pharmacology*
D012604:Scorpion Venoms; D013757:Tetraethylammonium Compounds; D018999:Charybdotoxin; D002586:Cesium; D001030:Apamin; D002110:Caffeine; D004533:Egtazic Acid; D019789:Tetraethylammonium; D015761:4-Aminopyridine; D009543:Nifedipine; D011188:Potassium; D002118:Calcium